Abstract:Fluoroquinolones are broad-spectrum antibiotics with good oral bioavailability. They are used for the treatment of a wide variety of infections, but there are restrictions on prescribing these drugs.Epidemiological studies have reported an increased risk of rare adverse effects. These include tendinopathy and tendon rupture, peripheral neuropathy and aortic aneurysm.Safe prescribing of fluroquinolones requires recognition of patients with risk factors for toxicity. Prompt drug discontinuation is recommended in… Show more
“…This drug class, which includes ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, and delafloxacin, directly inhibits bacterial DNA synthesis 1. Although fluoroquinolones became popular in large part because of their excellent oral bioavailability, because of their serious adverse reaction profile, they should only be used if other therapeutic options have been exhausted 2. In 2016, 2017, and 2018, the FDA issued drug safety communications that advised restricting fluoroquinolone use in patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated UTIs, given the risk of serious adverse reactions 3.…”
Fluoroquinolones, such as ciprofloxacin and levofloxacin, are broad-spectrum antibacterial agents that have historically been widely used for urinary tract infections, pneumonia, and intra-abdominal infections but are associated with several serious adverse reactions, including tendinopathy and tendon rupture, peripheral neuropathy, and aortic aneurysm. These drugs should not be used for uncomplicated infections unless no other antimicrobial treatment is feasible. This article describes a patient who experienced life-altering disability from a fluoroquinolone, reviews the adverse reactions of this drug class, and discusses recommended treatment for acute uncomplicated cystitis and asymptomatic bacteriuria.
“…This drug class, which includes ciprofloxacin, levofloxacin, moxifloxacin, ofloxacin, and delafloxacin, directly inhibits bacterial DNA synthesis 1. Although fluoroquinolones became popular in large part because of their excellent oral bioavailability, because of their serious adverse reaction profile, they should only be used if other therapeutic options have been exhausted 2. In 2016, 2017, and 2018, the FDA issued drug safety communications that advised restricting fluoroquinolone use in patients with acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated UTIs, given the risk of serious adverse reactions 3.…”
Fluoroquinolones, such as ciprofloxacin and levofloxacin, are broad-spectrum antibacterial agents that have historically been widely used for urinary tract infections, pneumonia, and intra-abdominal infections but are associated with several serious adverse reactions, including tendinopathy and tendon rupture, peripheral neuropathy, and aortic aneurysm. These drugs should not be used for uncomplicated infections unless no other antimicrobial treatment is feasible. This article describes a patient who experienced life-altering disability from a fluoroquinolone, reviews the adverse reactions of this drug class, and discusses recommended treatment for acute uncomplicated cystitis and asymptomatic bacteriuria.
“…This has been shown to reduce infectious complications compared to single agent prophylaxis with the majority of studies included within the metanalysis using fluoroquinolone as one of the agents, often in conjunction with an aminoglycoside (161). Recently, there has been concern with regards to increasing recognized adverse effects of fluoroquinolone antibiotics and their use in perioperative prophylaxis has been restricted in some regions (169,170). As a result, there has been an increased emphasis on alternative antibiotics for prophylaxis.…”
Section: Antibiotic Prophylaxis In Transrectal Biopsymentioning
Prostate cancer is a common and increasing malignancy in men. Tissue is generally obtained using prostate biopsy for diagnosis and risk stratification. There are many prostate biopsy techniques. Historically, the transrectal approach has been the most adopted. In many centers, however, there has a been a shift towards transperineal Note to the Reader: This chapter is part of the book Urologic Cancers (ISBN: 978-0-6453320-5-6), scheduled for publication in July 2022. The book is being published by Exon Publications,
“…Patients that were given quinolones and vancomycin had a strong association with developing post-ICU LTCI [ 16 ]. Fluoroquinolone can cause CNS side effects including psychosis, hallucinations, and convulsions, and it is postulated that these neurologic deficits are what may predispose patients to LTCI [ 20 ].…”
Long-term cognitive impairment (LTCI) is a phenomenon predominantly seen in patients within intensive care units (ICU) that causes chronic dysfunction, defined as new or worsening deficits in memory, attention, mental processing speed, executive function, intellectual function, and visual-spatial abilities for over 12 months, inhibiting the necessary return to baseline function without appropriate intervention. Our objective is to provide a guideline of nursing strategies to reduce LTCI through different studies that evaluate pharmacological and non-pharmacological methods. Current literature demonstrates that pharmacotherapy focused on neuronal protection as well as robust physical therapy regimens and regulated sleep schedules show promise in strengthening cognitive function and reducing LTCI. Future studies regarding LTCI should focus on the efficacy of specific pharmacological regimens, large-scale assessments of the implementation of physical therapy to reduce LTCI, as well as, specific interventions to reduce the incidence of delirium in the ICU.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.